Axicabtagene Ciloleucel (Yescarta)


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec.
 This review assesses axicabtagene ciloleucel (axi-cel; Yescarta), cell suspension in patient-specific single-infusion bag, target dose 2 × 106 CAR-positive viable T cells/kg body weight to maximum 108 cells, for IV infusion.
 Indication: Treatment adult patients diffuse large B-cell lymphoma high-grade is refractory first-line chemoimmunotherapy relapses within 12 months chemoimmunotherapy.